|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | 0.00% |
|
0.00% | -99.00% |
| Market Cap | 6.24M 4.43M 3.89M 3.63M 3.33M 424M 6.39M 43.06M 16.84M 210M 16.62M 16.26M 725M | P/E 2022 |
-2.09x | P/E 2023 | -0.45x |
|---|---|---|---|---|---|
| Enterprise Value | 64.5M 45.77M 40.22M 37.54M 34.45M 4.38B 66.09M 445M 174M 2.17B 172M 168M 7.5B | EV / Sales 2022 |
3.37x | EV / Sales 2023 | 1.35x |
| Free-Float |
52.66% | Yield 2022 * |
-
| Yield 2023 | - |
| Current year | 0 |  | 0 |
| 1 year | 0 | | 0 |
| 3 years | 0 | | 0.4 |
| 5 years | 0 | | 0.84 |
| 10 years | 0 | | 1.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Tougas
DFI | Director of Finance/CFO | - | 2023-11-19 |
Nelly Komari
CTO | Chief Tech/Sci/R&D Officer | - | 2021-05-31 |
Frédéric Dumais
IRC | Investor Relations Contact | - | 2019-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Richard MacKay
CHM | Chairman | 91 | 2018-07-24 |
Robert Raich
BRD | Director/Board Member | 74 | 2024-02-12 |
Steven Saviuk
CHM | Chairman | 67 | 2024-08-05 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 11/11/24 | Other | Investor Relations Manager | 0 | 0% | ||
| 11/11/24 | Other | Investor Relations Manager | 0 | 0% | ||
| 11/11/24 | Other | Investor Relations Manager | 0 | 0% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | - | - | 98 | |
| -1.20% | +4.24% | +58.90% | +166.70% | 1,089B | |
| -0.21% | +3.93% | +58.04% | +58.59% | 643B | |
| +0.71% | +4.06% | +37.84% | +76.21% | 465B | |
| -1.69% | +8.36% | +38.80% | +34.26% | 359B | |
| -0.51% | +3.35% | +39.00% | +43.76% | 303B | |
| +1.50% | +3.40% | +17.71% | +17.41% | 267B | |
| +0.79% | +4.32% | -25.07% | -36.02% | 226B | |
| -3.42% | +5.84% | +27.62% | +65.45% | 212B | |
| -1.71% | +1.87% | +16.24% | +74.39% | 167B | |
| Average | -0.31% | +4.57% | +29.90% | +55.64% | 373.11B | |
| Weighted average by Cap. | -0.47% | +5.14% | +40.85% | +81.19% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 27.74M 19.69M 17.3M 16.15M 14.82M 1.89B 28.43M 192M 74.89M 933M 73.93M 72.32M 3.23B | 53.91M 38.26M 33.62M 31.38M 28.8M 3.66B 55.24M 372M 146M 1.81B 144M 141M 6.27B |
| Net income | -25.75M -18.27M -16.06M -14.99M -13.75M -1.75B -26.38M -178M -69.5M -866M -68.6M -67.11M -2.99B | -27.81M -19.74M -17.34M -16.19M -14.86M -1.89B -28.49M -192M -75.06M -935M -74.1M -72.49M -3.23B |
| Net Debt | 38.94M 27.64M 24.28M 22.67M 20.8M 2.65B 39.9M 269M 105M 1.31B 104M 102M 4.53B | 58.26M 41.35M 36.33M 33.91M 31.12M 3.96B 59.7M 402M 157M 1.96B 155M 152M 6.77B |
Employees
70
Sector
Pharmaceuticals
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VPHIF Stock
Select your edition
All financial news and data tailored to specific country editions
